Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology
- 13 September 2012
- journal article
- practice guideline
- Published by Wiley in British Journal of Haematology
- Vol. 159 (4), 427-429
- https://doi.org/10.1111/bjh.12052
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: A study in 9 Swiss laboratoriesThrombosis Research, 2012
- Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatranBlood Coagulation & Fibrinolysis, 2012
- Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controlsThrombosis and Haemostasis, 2012
- Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacementThrombosis Research, 2011
- Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assaysJournal of Thrombosis and Haemostasis, 2011
- Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assaysThrombosis and Haemostasis, 2011
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitorThrombosis and Haemostasis, 2010
- Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activityThrombosis and Haemostasis, 2010
- In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilateThrombosis and Haemostasis, 2007